These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 6219711)

  • 21. Inhibition of hepatitis-B-virus DNA polymerase by phosphonoformate: studies on its mode of action.
    Hess G; Arnold W; Meyer zum Büschenfelde KH
    J Med Virol; 1980; 5(4):309-16. PubMed ID: 6453206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro effect of foscarnet on expansion of T-cells from people with LAS and AIDS.
    Beldekas JC; Levy EM; Black P; Von Krogh G; Sandstrom E
    Lancet; 1985 Nov; 2(8464):1128-9. PubMed ID: 2865599
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparison of foscarnet and foscarnet esters as anti-influenza virus agents.
    Strid S; Ekström C; Datema R
    Chemotherapy; 1989; 35(1):69-76. PubMed ID: 2524368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reversible inhibition of cytomegalovirus replication by phosphonoformate.
    Wahren B; Oberg B
    Intervirology; 1980; 14(1):7-15. PubMed ID: 6259084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic inhibition of human T-cell lymphotropic virus type III replication in vitro by phosphonoformate and recombinant alpha-A interferon.
    Hartshorn KL; Sandstrom EG; Neumeyer D; Paradis TJ; Chou TC; Schooley RT; Hirsch MS
    Antimicrob Agents Chemother; 1986 Jul; 30(1):189-91. PubMed ID: 3019235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of phosphonoformic acid, dietary phosphate and the Hyp mutation on kinetically distinct phosphate transport processes in mouse kidney.
    Tenenhouse HS; Klugerman AH; Neal JL
    Biochim Biophys Acta; 1989 Sep; 984(2):207-13. PubMed ID: 2527564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanism of phosphaturia elicited by administration of phosphonoformate in vivo.
    VanScoy M; Loghman-Adham M; Onsgard M; Szczepanska-Konkel M; Homma S; Knox FG; Dousa TP
    Am J Physiol; 1988 Nov; 255(5 Pt 2):F984-94. PubMed ID: 2847555
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mode of estrogen action on cell proliferation in CAMA-1 cells: II. Sensitivity of G1 phase population.
    Leung BS; Potter AH
    J Cell Biochem; 1987 Jul; 34(3):213-25. PubMed ID: 3611201
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of alkaline phosphatase and the glycoprotein hormone alpha subunit in HeLa cells by inhibitors of DNA polymerase.
    Cox GS; Park KH
    Arch Biochem Biophys; 1982 Jun; 216(1):234-46. PubMed ID: 6179479
    [No Abstract]   [Full Text] [Related]  

  • 30. Micromethod for phosphonoformate inhibition assay of hepatitis B viral DNA polymerase.
    Lin HJ; Wu PC; Lai CL; Chak W
    Clin Chem; 1984 Apr; 30(4):549-52. PubMed ID: 6231137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of PFA (trisodium phosphonoformate) after i.v. and p.o. administration to beagle dogs and rabbits.
    Ritschel WA; Grummich KW; Hussain SA
    Methods Find Exp Clin Pharmacol; 1985 Jan; 7(1):41-8. PubMed ID: 3157841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Action of ribamidyl and phosphonoformic acid on the reproduction of the HTLV-III retrovirus in vitro].
    Nesterchuk SL; Gribencha SV; Barinskiĭ IF; Zhadanov VM
    Vopr Virusol; 1987; 32(3):364-6. PubMed ID: 2960081
    [No Abstract]   [Full Text] [Related]  

  • 33. Determination of phosphonoformate (foscarnet) in biological fluids by ion-pair reversed-phase liquid chromatography.
    Pettersson KJ; Nordgren T; Westerlund D
    J Chromatogr; 1989 Mar; 488(2):447-55. PubMed ID: 2526150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enrichment of early HSV-induced proteins in phosphonoformate-treated cells.
    Lehtinen MO; Lehtinen TK; Leinikki PO
    Acta Virol; 1984 Jan; 28(1):11-8. PubMed ID: 6143492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Foscarnet.
    Lancet; 1985 Sep; 2(8456):648-9. PubMed ID: 2863637
    [No Abstract]   [Full Text] [Related]  

  • 36. Topical treatment of recurrent genital herpes simplex virus infections with trisodium phosphonoformate (foscarnet): double blind, placebo controlled, multicentre study.
    Barton SE; Munday PE; Kinghorn GR; van der Meijden WI; Stolz E; Notowicz A; Rashid S; Schuller JL; Essex-Cater AJ; Kuijpers MH
    Genitourin Med; 1986 Aug; 62(4):247-50. PubMed ID: 2942457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful treatment with trisodium phosphonoformate for primary cytomegalovirus infection after heart transplantation.
    Locke TJ; Odom NJ; Tapson JS; Freeman R; McGregor CG
    J Heart Transplant; 1987; 6(2):120-2. PubMed ID: 3040944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mode of action of erythropoietin (Epo) in an Epo-dependent murine cell line. II. Cell cycle dependency of Epo action.
    Tsuda H; Sawada T; Kawakita M; Takatsuki K
    Exp Hematol; 1989 Mar; 17(3):218-22. PubMed ID: 2917620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical experiences with phosphonoformate (foscarnet) treatment of viral diseases following renal transplantation.
    Ahlmén J; Wijnween AC; Brynger H; Lycke E
    Scand J Urol Nephrol Suppl; 1985; 92():41-4. PubMed ID: 3008316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sensitivity of HSV clinical isolates to foscarnet and in vitro dual combination of foscarnet and acyclovir.
    Al-Samarai A; Kinghorn G; Potter C
    Chemioterapia; 1987 Jun; 6(2 Suppl):665-6. PubMed ID: 2855616
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.